Journal
CANCER INVESTIGATION
Volume 26, Issue 2, Pages 208-216Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/07357900701788122
Keywords
5-azacytidine; 5-aza-2 '-deoxycytidine; lenalidomide; DNA methylation; myelodysplastic syndromes
Categories
Funding
- NCI NIH HHS [5P01 CA108631, CA105771] Funding Source: Medline
Ask authors/readers for more resources
Myelodysplastic syndromes (MDS) are a group of disorders characterized by progressive cytopenias and transformation to acute leukemia. Over the last four years, we have experienced a revolution in the treatment of MDS. Three drugs were approved in the U.S. Two of them, 5-azacitidine and 5-aza-2'-deoxycitidine, induce DNA hypomethylation. The third agent, lenalidomide, is a thalidomide analogue with significant activity in a subset of patients with low-risk MDS, anemia and chromosome 5 alterations. Several other agents are being evaluated in MDS. In this short review, we will summarize our current approach to the therapy of patients with MDS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available